文献速递急性肾损伤

左乙拉西坦使用与急性肾损伤风险的人群研究

Population-Based Study of Risk of AKI with Levetiracetam.
PubMed 文献 · Clin J Am Soc Nephrol · 2018-12-11

该研究为加拿大安大略省成人癫痫患者的回顾性队列研究,将2004至2017年间新处方左乙拉西坦的门诊患者与按CKD分期、近期癫痫发作及倾向评分匹配的非使用者比较。结果显示左乙拉西坦使用与30天内急性肾损伤风险无显著关联(OR 1.24,95%CI 0.62-2.47),180天内及血肌酐变化亦无显著差异。

要点

  • 左乙拉西坦新使用者30天内AKI风险与未使用者无显著差异。
  • 180天内AKI风险及血肌酐变化同样无显著关联。
  • 基于人群的队列研究未证实监管警告的AKI风险信号。

核心结论

  • 在本基于人群的研究中,左乙拉西坦使用与急性肾损伤风险升高无关联。

研究设计与样本

  • 加拿大安大略省成人癫痫患者的基于人群回顾性队列研究。
  • 2004年1月1日至2017年3月1日新接受左乙拉西坦门诊处方的患者,按CKD分期、既往90天癫痫记录及倾向评分logit匹配两个非使用者。
  • 共匹配3980例左乙拉西坦使用者与7960例非使用者,平均年龄55岁,女性占51%。
  • 主要结局为入组后30天内因AKI的医院就诊(急诊或住院),次要结局为180天内AKI及血清肌酐浓度变化。

主要发现

  • 30天内AKI事件:左乙拉西坦组13例(0.33%),非使用者组21例(0.26%),OR 1.24(95%CI 0.62-2.47),无显著关联。
  • 180天内AKI:OR 0.70(95%CI 0.43-1.13),无显著关联。
  • 左乙拉西坦使用者与非使用者之间血清肌酐浓度变化无显著差异。

临床怎么用

  • 对于癫痫患者,左乙拉西坦处方决策时无需因担忧AKI风险而过度回避,但仍需基于个体情况常规监测肾功能。

局限性

  • 主要结局基于医疗诊断编码评估,可能存在错分偏倚。
  • 血肌酐变化仅在具有实验室测量数据的亚组中评估。
  • 观察性设计不能完全排除残余混杂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Regulatory agencies warn about the risk of AKI with levetiracetam use on the basis of information from case reports. We conducted this study to determine whether new levetiracetam use versus nonuse is associated with a higher risk of AKI. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This was a population-based retrospective cohort study of adults with epilepsy in Ontario, Canada. Patients who received a new outpatient prescription for levetiracetam between January 1, 2004 and March 1, 2017 were matched to two nonusers on stage of CKD, recorded seizure in the prior 90 days, and logit of a propensity score for levetiracetam use. The primary outcome was a hospital encounter (emergency department visit or hospitalization) with AKI within 30 days of cohort entry. Secondary outcomes were AKI within 180 days and change in the concentration of serum creatinine. We assessed the primary outcome using health care diagnosis codes. We evaluated the change in the concentration of serum creatinine in a subpopulation with laboratory measurements. RESULTS: We matched 3980 levetiracetam users to 7960 nonusers (mean age 55 years, 51% women). Levetiracetam use was not significantly associated with a higher risk of AKI within 30 days (13 [0.33%] events in levetiracetam users and 21 [0.26%] events in nonusers [odds ratio, 1.24; 95% confidence interval, 0.62 to 2.47]). Similarly, there was no significant association with AKI within 180 days (odds ratio, 0.70; 95% confidence interval, 0.43 to 1.13). The change in the concentration of serum creatinine did not significantly differ between levetiracetam users and nonusers. CONCLUSIONS: In this population-based study levetiracetam use was not associated with a higher risk of AKI. PODCAST: This article contains a podcast at https://www.asn-online.org/media/podcast/CJASN/2018_12_11_Yau_Podcast.mp3.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Yau K, Burneo JG, Jandoc R, et al. Population-Based Study of Risk of AKI with Levetiracetam. Clin J Am Soc Nephrol. 2018. PMID: 30538089. doi:10.2215/CJN.07490618

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。